Sickle Cell Disease: Progress and Opportunities for Equity
Marshall W. Nirenberg Lecture | to
Alexis A. Thompson, M.D., MPH
Chief of the Division of Hematology
Children's Hospital of Philadelphia
Alexis Thompson's career spans bench to beside and reached a historic milestone in 2023, with the approval of the first two gene therapies for sickle cell disease. Now Chief of the Division of Hematology at Children's Hospital of Philadelphia (CHOP), PA, USA, Thompson led clinical research on the lentiviral vector therapy lovotibeglogene autotemcel (lovo-cel) for severe sickle cell disease, approved in the USA for use in adolescents and adults.
This page was last updated on Monday, August 5, 2024